In recent years, artificial intelligence (AI) has been revolutionizing various sectors, and drug development is no exception. Projections indicate that the global AI in drug discovery market is set to reach $4.6 billion in size by 2030, expanding at a solid 27.6% compound annual growth rate.
A recent study by consultancy giant Boston Consulting Group (BCG) highlighted that drugs discovered using AI have an 80% to 90% success rate in Phase I clinical trials, significantly higher than the historical average of Phase I success rates. This indicates that AI is highly effective at identifying molecules with promising drug-like properties.
